
Sign up to save your podcasts
Or
We love to hear from our listeners. Send us a message.
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
Subscribe to the podcast!
Apple | Spotify | YouTube
4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
Subscribe to the podcast!
Apple | Spotify | YouTube
757 Listeners
177 Listeners
30,845 Listeners
3,195 Listeners
32,291 Listeners
2,648 Listeners
272 Listeners
318 Listeners
29 Listeners
2,135 Listeners
147 Listeners
18 Listeners
15 Listeners
54 Listeners
152 Listeners